Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Acitretin

FDA-approved product (capsule, oral), marketed as Acitretin, Soriatane.

Registered studies
42
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Acitretin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psoriasis
  • Psoriasis vulgaris

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Retinoids for treatment of psoriasis
FDA pharmacologic class
Retinoid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA34.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli20.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

42registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Acitretin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Acitretin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)

    NCT07234838 · start 2026-02-01

    Registered record
    Registry ID
    NCT07234838
    Conditions
    Psoriasis; Condyloma Acuminata; Biotherapies
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2026-02-01
    Completion
    2028-08-01
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis; Condyloma Acuminata; Biotherapies
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice

    NCT07336641 · start 2026-01

    Registered record
    Registry ID
    NCT07336641
    Conditions
    Psoriasis; Atopic Dermatitis; Vitiligo; Alopecia Areata; Hidradenitis Suppurativa
    Interventions
    Conventional Systemic Therapies; Biologic Therapies
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-01
    Completion
    2028-01
    Enrolment
    20,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis; Atopic Dermatitis; Vitiligo; Alopecia Areata +1 more
    InterventionConventional Systemic Therapies; Biologic Therapies
    PhaseNot recorded
    Registry statusNot yet recruiting

  • A Prospective Cohort Study on Primary Cutaneous Amyloidosis

    NCT06998875 · start 2025-03-01

    Registered record
    Registry ID
    NCT06998875
    Conditions
    Primary Cutaneous Amyloidosis
    Interventions
    Tofacitinib and Acitretin Capsules.; Acitretin Capsules.
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-03-01
    Completion
    2025-12
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Cutaneous Amyloidosis
    InterventionTofacitinib and Acitretin Capsules.; Acitretin Capsules.
    PhasePhase 4
    Registry statusRecruiting

  • Comparative Efficacy of Apremilast and Acitretin in Moderate-to-Severe Hidradenitis Suppurativa

    NCT07708480 · start 2024-12-22

    Registered record
    Registry ID
    NCT07708480
    Conditions
    Hidradenitis Suppurativa
    Interventions
    Apremilast; Acitretin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-12-22
    Completion
    2025-05-22
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHidradenitis Suppurativa
    InterventionApremilast; Acitretin
    PhasePhase 4
    Registry statusCompleted

  • Systemic Treatment Options for Generalized Lichen Planus

    NCT06739551 · start 2024-12-10

    Registered record
    Registry ID
    NCT06739551
    Conditions
    Lichen Planus
    Interventions
    Methotrexate (drug); Acitretin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-12-10
    Completion
    2025-03-20
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLichen Planus
    InterventionMethotrexate (drug); Acitretin
    PhasePhase 2
    Registry statusNot yet recruiting

  • Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis

    NCT04239859 · start 2024-01

    Registered record
    Registry ID
    NCT04239859
    Conditions
    Plaque Psoriasis
    Interventions
    secukinumab; Methotrexate; Cyclosporin A; Acitretin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2024-01
    Completion
    2027-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Psoriasis
    Interventionsecukinumab; Methotrexate; Cyclosporin A; Acitretin
    PhasePhase 4
    Registry statusNot yet recruiting

  • Plexin B2 Gene Expression and Polymorphisms in Psoriasis

    NCT05184348 · start 2021-09-01

    Registered record
    Registry ID
    NCT05184348
    Conditions
    Psoriasis Vulgaris
    Interventions
    Narrow band Ultraviolet B phototherapy group; Acitretin group; Acitretin plus Narrow band Ultraviolet B phototherapy group
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-09-01
    Completion
    2023-03-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis Vulgaris
    InterventionNarrow band Ultraviolet B phototherapy group; Acitretin group; Acitretin plus Narrow band Ultraviolet B phototherapy group
    PhasePhase 1
    Registry statusCompleted

  • Effect of Acitretin Versus Narrowband Ultraviolet B on Neopterin Level in Psoriatic Patients .

    NCT05401006 · start 2021-06-05

    Registered record
    Registry ID
    NCT05401006
    Conditions
    Psoriasis
    Interventions
    Acitretin 25Mg Cap; Narrowband ultraviolet B
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-06-05
    Completion
    2023-06-05
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionAcitretin 25Mg Cap; Narrowband ultraviolet B
    PhasePhase 4
    Registry statusUnknown

  • Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)

    NCT05320159 · start 2021-02-03

    Registered record
    Registry ID
    NCT05320159
    Conditions
    Psoriasis
    Interventions
    Secukinumab
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-02-03
    Completion
    2021-03-31
    Enrolment
    17,743

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionSecukinumab
    PhaseNot recorded
    Registry statusCompleted

  • Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis

    NCT04537689 · start 2020-12-10

    Registered record
    Registry ID
    NCT04537689
    Conditions
    Plaque Psoriasis
    Interventions
    Ixekizumab; Methotrexate; Cyclosporin A; Acitretin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2020-12-10
    Completion
    2027-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Psoriasis
    InterventionIxekizumab; Methotrexate; Cyclosporin A; Acitretin
    PhasePhase 4
    Registry statusRecruiting

  • Combined Effect of Acitretin and Narrow Band Ultraviolet B on Vitiligo Repigmentation

    NCT04245319 · start 2020-01-01

    Registered record
    Registry ID
    NCT04245319
    Conditions
    Hyperlipidemias; Xerosis; Depression; Liver Diseases
    Interventions
    Acitretin; Narrow band ultraviolet B
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-01-01
    Completion
    2021-12-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperlipidemias; Xerosis; Depression; Liver Diseases
    InterventionAcitretin; Narrow band ultraviolet B
    PhaseNot applicable
    Registry statusUnknown

  • RA Effect on Cell Surface Molecules in Vivo

    NCT03753867 · start 2019-01-07

    Registered record
    Registry ID
    NCT03753867
    Conditions
    HIV Infections
    Interventions
    Acitretin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2019-01-07
    Completion
    2019-05-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAcitretin
    PhasePhase 1
    Registry statusWithdrawn

  • Omentin-1 Level in Psoriatic Patients Treated With Narrowband Ultraviolet B Phototherapy Versus Acitretin

    NCT05203354 · start 2018-09-01

    Registered record
    Registry ID
    NCT05203354
    Conditions
    Psoriasis
    Interventions
    Narrowband Ultraviolet B; Acitretin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-09-01
    Completion
    2021-08-15
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionNarrowband Ultraviolet B; Acitretin
    PhasePhase 4
    Registry statusCompleted

  • Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules

    NCT02715960 · start 2015-12

    Registered record
    Registry ID
    NCT02715960
    Conditions
    Psoriasis Vulgaris
    Interventions
    Acitretin Capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2015-12
    Completion
    2017-12
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis Vulgaris
    InterventionAcitretin Capsules
    PhasePhase 2
    Registry statusUnknown

  • Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles

    NCT02181790 · start 2014-06

    Registered record
    Registry ID
    NCT02181790
    Conditions
    Psoriasis, Skin or Nails
    Interventions
    Excimer laser; Acitretin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2014-06
    Completion
    2014-12
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis, Skin or Nails
    InterventionExcimer laser; Acitretin
    PhasePhase 4
    Registry statusTerminated